This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Giugliano, R. P. Articles by Braunwald, E. Search for Related Content PubMed PubMed Citation Articles by Giugliano, R. P. Articles by Braunwald, E. Related Collections Fibrinolysis Catheter-based coronary interventions: stents Acute myocardial infarction Related Article

(Circulation. 2003;108:2828.)
© 2003 American Heart Association, Inc.

Focused Perspectives

Selecting the Best Reperfusion Strategy in ST-Elevation Myocardial Infarction

It’s All a Matter of Time

Robert P. Giugliano, MD, SM; Eugene Braunwald, MD

From The TIMI Study Group, Cardiovascular Division, Brigham and Women’s Hospital, and the Department of Medicine, Harvard Medical School, Boston, Mass.

Correspondence to: Eugene Braunwald, MD, TIMI Study Group, 350 Longwood Ave, Boston. MA 02115. E-mail ebraunwald@partners.org

Key Words: Editorials • myocardial infarction • reperfusion • angioplasty • fibrinolysis

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
The primary goal of treatment of acute coronary occlusion is the achievement of early, complete, and sustained epicardial and myocardial reperfusion. Fibrinolytic therapy was first attempted in 1958,¹ and, until recently, constituted the dominant approach for reperfusion. Primary coronary intervention (PCI) is now being used as an alternative to fibrinolysis with increasing frequency. This approach is supported by a recent comprehensive meta-analysis of 23 trials that demonstrated reductions in death, recurrent myocardial infarction, and stroke of 2, 4, and 1 per 100 patients treated through 30 days, respectively.² Attempts to improve the efficacy of the standard pharmacological reperfusion regimen consisting of aspirin, unfractionated heparin, and front-loaded tissue plasminogen activator using more fibrin specific fibrinolytic agents, bolus preparations, more potent antithrombotic drugs, and platelet glycoprotein IIb/IIIa inhibitors have not reduced mortality.³ In contrast, a meta-analysis of clinical trials that compared prehospital fibrinolysis to hospital administration demonstrated a 17% relative reduction in mortality when time to treatment was reduced by an average of 1 hour.⁴

See p 2851

Thus, it became logical to compare these 2 improvements in reperfusion therapy in the Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) trial,⁵ in which the median time from symptom onset to therapy for patients receiving prehospital fibrinolysis was 130 minutes, and was 60 minutes longer in the primary PCI group. There was no difference at 30 days in the primary composite of death, non-fatal reinfarction, and non-fatal stroke (8.2% for fibrinolysis versus 6.2% for PCI, P=0.29) or in mortality . . . [Full Text of this Article]

Related Article:

Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty: Data From the CAPTIM Randomized Clinical Trial

Philippe Gabriel Steg, Eric Bonnefoy, Sylvie Chabaud, Frédéric Lapostolle, Pierre-Yves Dubien, Pascal Cristofini, Alain Leizorovicz, Paul Touboul for the Comparison of Angioplasty and Prehospital Thrombolysis In acute Myocardial infarction (CAPTIM) Investigators
Circulation 2003 108: 2851-2856. [Abstract] [Full Text]

This article has been cited by other articles:

				B Nallamothu, K A A Fox, B M Kennelly, F Van de Werf, J M Gore, P G Steg, C B Granger, O H Dabbous, E Kline-Rogers, K A Eagle, et al. Relationship of treatment delays and mortality in patients undergoing fibrinolysis and primary percutaneous coronary intervention. The Global Registry of Acute Coronary Events Heart, December 1, 2007; 93(12): 1552 - 1555. [Abstract] [Full Text] [PDF]

				I. Kusama, K. Hibi, M. Kosuge, N. Nozawa, H. Ozaki, H. Yano, S. Sumita, K. Tsukahara, J. Okuda, T. Ebina, et al. Impact of Plaque Rupture on Infarct Size in ST-Segment Elevation Anterior Acute Myocardial Infarction J. Am. Coll. Cardiol., September 25, 2007; 50(13): 1230 - 1237. [Abstract] [Full Text] [PDF]

				B. K. Nallamothu, H. M. Krumholz, D. T. Ko, K. A. LaBresh, S. Rathore, M. T. Roe, and L. Schwamm Development of Systems of Care for ST-Elevation Myocardial Infarction Patients: Gaps, Barriers, and Implications Circulation, July 10, 2007; 116(2): e68 - e72. [Full Text] [PDF]

				D. D. Mayer and A. Rosenfeld Symptom Interpretation in Women With Diabetes and Myocardial Infarction: A Qualitative Study The Diabetes Educator, November 1, 2006; 32(6): 918 - 924. [Abstract] [Full Text] [PDF]

				E. J. van den Bos, T. Baks, A. D. Moelker, W. Kerver, R.-J. van Geuns, W. J. van der Giessen, D. J. Duncker, and P. A. Wielopolski Magnetic resonance imaging of haemorrhage within reperfused myocardial infarcts: possible interference with iron oxide-labelled cell tracking? Eur. Heart J., July 1, 2006; 27(13): 1620 - 1626. [Abstract] [Full Text] [PDF]

				Part 5: Acute Coronary Syndromes Circulation, November 29, 2005; 112(22_suppl): III-55 - III-72. [Full Text] [PDF]

				A. G. Rosenfeld, A. Lindauer, and B. G. Darney Understanding Treatment-Seeking Delay in Women with Acute Myocardial Infarction: Descriptions of Decision-Making Patterns Am. J. Crit. Care., July 1, 2005; 14(4): 285 - 293. [Abstract] [Full Text] [PDF]

				B. J. Gersh, G. W. Stone, H. D. White, and D. R. Holmes Jr Pharmacological Facilitation of Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Is the Slope of the Curve the Shape of the Future? JAMA, February 23, 2005; 293(8): 979 - 986. [Abstract] [Full Text] [PDF]

				K. C. Wollert and H. Drexler Clinical Applications of Stem Cells for the Heart Circ. Res., February 4, 2005; 96(2): 151 - 163. [Abstract] [Full Text] [PDF]

				M. Gyongyosi, H. Domanovits, W. Benzer, M. Haugk, B. Heinisch, G. Sodeck, R. Hodl, G. Gaul, G. Bonner, J. Wojta, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study Eur. Heart J., December 1, 2004; 25(23): 2125 - 2133. [Abstract] [Full Text] [PDF]

				R. Manfredini, B. Boari, P. G. Steg, E. Bonnefoy, P. Touboul, S. Chabaud, A. Leizorovicz, F. Lapostolle, P.-Y. Dubien, and P. Cristofini Impact of Time to Treatment on Mortality After Prehospital Fibrinolysis or Primary Angioplasty * Response Circulation, May 11, 2004; 109(18): e219 - e219. [Full Text] [PDF]

				Time to Treatment Affects the Relative Benefits of Reperfusion Strategies Journal Watch Cardiology, February 20, 2004; 2004(220): 2 - 2. [Full Text]

				Prehospital Thrombolysis vs. Primary Angioplasty for Acute MI: Time to Treatment Matters Journal Watch (General), January 20, 2004; 2004(120): 6 - 6. [Full Text]